
INNOVATION IN THE DELIVERY OF INHALED NITRIC OXIDE

## GENOSYL DELIVERY SYSTEM

SIMPLIFIED TANKLESS SOLUTION

### **GENOSYL® DS** is the Only Device Approved to Accurately Deliver iNO in Low-Flow Anesthesia

- Streamlines workflow simple setup and initiation, proven to be able to be completed by Anesthesia providers
- Supports physician's preference no need to change practice to deliver iNO
- Approved for use with low-flow anesthesia, which:
  - Maintains body temperature, and reduce water loss, which may prevent postoperative complications (e.g.: hypothermia, pneumonia, etc)¹
  - Decreases the amount of anesthetic agents used, thereby reducing cost<sup>2,3</sup>
  - Reduces greenhouse gas emissions by cutting the amount of unused anesthetics agents release into environment<sup>4</sup>



Bilgi M, Goksu S, Mizrak A, Cevik C, Gul R, Koruk S, Sahin L. Comparison of the effects of low-flow and high-flow inhalational anaesthesia with nitrous oxide and desflurane on mucociliary activity and pulmonary function tests. European Journal of Anaesthesiology 2011;28(4): 279-283.

<sup>2.</sup> Hayu AL, Hanindito E, Hamzah H, Utariani A. Effectiveness of high-flow inhalation anesthesia technique using isoflurane compared to low-flow inhalation anesthesia technique using sevoflurane and isoflurane in terms of cost and safety. Bali J Anaesthesiol. 2019;3:170-173.

<sup>3.</sup> Cotter SM, Petros AJ, Doré CJ, Barber ND, White DC. Low-flow anaesthesia. Anaesthesia. 1991;46:1009-1012.

<sup>4.</sup> Varughese S, Ahmed R. Environmental and occupational considerations of anesthesia: a narrative review and update.





#### MEDICAL INFORMATION



#### INVENTORY MANAGEMENT



#### TECHNICAL SUPPORT



#### TRAINING AND EDUCATION



# Supporting innovation and change, our experienced, Registered RTs provide 24/7/365 support and a customized partnership to ensure success

- 24 hours a day, 7 days a week, 365 days a year
- Distribution centers nationwide
- Over 2 million patient hours

**EVERY DAY, EVERY HOUR, EVERY MINUTE,** 

For more information, contact your VERO Biotech Representative or the Partnership365™ Care Team at **vero-biotech.com** or **1.877.337.4118** 

#### INDICATION AND IMPORTANT SAFETY INFORMATION

GENOSYL® is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

- $\bullet \ \ \mathsf{GENOSYL} \ \mathsf{is} \ \mathsf{contraindicated} \ \mathsf{in} \ \mathsf{the} \ \mathsf{treatment} \ \mathsf{of} \ \mathsf{neonates} \ \mathsf{dependent} \ \mathsf{on} \ \mathsf{right-to-left} \ \mathsf{shunting} \ \mathsf{of} \ \mathsf{blood}.$
- Abrupt discontinuation of GENOSYL (nitric oxide) gas, for inhalation may lead to worsening oxygenation and increasing pulmonary artery pressure.
- Methemoglobin, NO2, and PaO2 should be monitored during nitric oxide administration.
- In patients with pre-existing left ventricular dysfunction, GENOSYL may increase pulmonary capillary wedge pressure leading to pulmonary edema.
- $\bullet\,$  The most common adverse reaction is hypotension.
- Nitric oxide donor compounds may have an additive effect with GENOSYL on the risk of developing methemoglobinemia.
- GENOSYL must be administered using a calibrated GENOSYL Delivery System. Only validated ventilator systems or nasal cannulas should be used in conjunction with GENOSYL.
- NO2, nitric dioxide; OR, operating room; PaO2, partial pressure of oxygen.



